$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Globally, ischemic heart disease (IHD) has only grown in its mortality and burden on patients and the healthcare system. According to the American Heart Association, the number of deaths attributable to IHD from 1990 to 2021 has increased by 74% worldwide1. This is additionally true within the United States, where the Center for Disease Control cites that one in twenty adults has been diagnosed with coronary artery disease (CAD), and about one in five mortalities are due to cardiovascular disease, which is equivalent to a person dying from cardiovascular disease every 33 s2. This burden of disease stresses the healthcare system, in which over $250 billion was spent on patients with cardiovascular disease from 2019 to 20202. Given the ubiquitous nature of cardiovascular disease and the severe burden to both patient and provider, it is imperative to continue investigations into innovative and novel therapeutics.
To achieve such goals, clinically relevant animal models must be employed yet scrutinized to meet the standards of reproducible and translational research. Animal models have been questioned for a multitude of reasons, including disparate animal species with variable pharmacokinetics, differing protocols for inducing the desired disease state, variations in drug dosing and schedules, poor standardization of randomizing animals, follow-up duration, and blinding of investigators, and finally, small experimental groupings3. We have experimentally refined and standardized the protocol not only of the overall animal model to represent IHD but also the surgical protocol, animal randomization, drug delivery and duration, and subsequent outcomes. In regard to IHD, swine represent an optimal animal model due to their significant similarities in cardiac anatomy and physiology to humans. Importantly, swine have similar coronary artery distribution as humans and minimal collateral circulation, making the induction of ischemia a reliable representation of the development of atherosclerosis in humans. Additionally, swine have similar metabolism, proteomic profile, and immune system to humans, which makes analyzing the molecular impact of therapeutics more meaningful4. With this in mind, the animal model employed in this protocol is best suited to reproducibly represent human cardiovascular pathophysiology.
Our lab utilizes the surgical placement of an ameroid constrictor on the LCx, allowing for the chronic induction of myocardial ischemia. Employing this technique to chronically induce ischemia yields unique advantages over acute ligation. One is the extensive research literature from multiple decades employing this device5. Additionally, it allows for the reliable clinical simulation of gradual coronary narrowing due to atherosclerotic development in humans and, finally, the improvement in animal mortality by sparing myocardium that would have had complete blood flow cessation6. The ameroid constrictor has two parts: a titanium outer ring and an inner hygroscopic plastic layer. When placed around the coronary artery, the inner ring will subsequently absorb bodily fluids and swell inward due to the restrictive steel sleeve over a two-to-four-week period7. The strategy of placement around the LCx confers mortality benefits as this is the smallest of the three major coronary arteries and affects approximately 20% of the myocardium7. To uniformly produce the ischemic area, the ameroid should be placed at the LCx takeoff before branching the obtuse marginal arteries.
Further consideration employed by this protocol is the confirmatory coronary blood flow mapping to determine the induction of ischemia and the use of the correct territory in investigating the myocardial effects of therapeutics. For this purpose, we employ gold microsphere injection from BioPhysics Assay Laboratory, Inc. at the time of ameroid placement when the LCx is completely occluded. The section with the lowest quantification of gold microspheres will then represent the most ischemic left ventricular territory. The importance of mapping cannot be overstated when determining the molecular modifications produced by experimental treatment. Additionally, the use of isotope-labeled microspheres provides a cost-effective method as compared to cardiac magnetic resistance imaging for the determination of myocardial perfusion8.
Lastly, the model described here considers the well-known variation among sexes in the development of cardiovascular disease and subsequent therapeutic response. Too often, preclinical animal models fail to faithfully represent differences in the human population; thus, we match the sex of the swine utilized in the control and experimental groups between female and intact male swine. We have previously employed this to determine sex-based responses to novel treatments9. Further adding to the translatability of this protocol is the use of randomization of treatment groups and blinding of the investigator analyzing the cardiac functional and myocardial perfusion parameters of each swine.